Daiwa Securities Group
BBIO icon

Daiwa Securities Group’s BridgeBio Pharma BBIO Stock Holding History

Daiwa Securities Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
5,991
-151
-2% -$10.6K ﹤0.01% 992
2026
Q1 		$456K Buy
6,142
+1,225
+25% +$88.8K ﹤0.01% 934
2025
Q4 		$376K Buy
4,917
+4,316
+718% +$283K ﹤0.01% 938
2025
Q3 		$31K Sell
601
-63
-9% -$3.07K ﹤0.01% 1120
2025
Q2 		$29K Buy
664
+40
+6% +$1.46K ﹤0.01% 1087
2025
Q1 		$22K Hold
624
– – ﹤0.01% 1066
2024
Q4 		$17K Sell
624
-31,085
-98% -$803K ﹤0.01% 1090
2024
Q3 		$807K Sell
31,709
-4,000
-11% -$105K ﹤0.01% 767
2024
Q2 		$904K Buy
35,709
+35,059
+5,394% +$959K ﹤0.01% 726
2024
Q1 		$20K Sell
650
-61
-9% -$2.07K ﹤0.01% 1136
2023
Q4 		$29K Buy
711
+161
+29% +$4.83K ﹤0.01% 1107
2023
Q3 		$15K Hold
550
– – ﹤0.01% 1109
2023
Q2 		$9K Sell
550
-7,747
-93% -$117K ﹤0.01% 1142
2023
Q1 		$138K Buy
8,297
+1,522
+22% +$17.7K ﹤0.01% 962
2022
Q4 		$52K Sell
6,775
-2,033
-23% -$19.5K ﹤0.01% 1032
2022
Q3 		$88K Buy
8,808
+8,258
+1,501% +$85.8K ﹤0.01% 1010
2022
Q2 		$5K Buy
550
+121
+28% +$1.01K ﹤0.01% 1169
2022
Q1 		$4K Hold
429
– – ﹤0.01% 1187
2021
Q4 		$7K Sell
429
-84
-16% -$3.55K ﹤0.01% 1166
2021
Q3 		$24K Buy
513
+218
+74% +$11.7K ﹤0.01% 1092
2021
Q2 		$18K Hold
295
– – ﹤0.01% 1022
2021
Q1 		$18K Buy
295
+64
+28% +$4.19K ﹤0.01% 1015
2020
Q4 		$16K Sell
231
-466
-67% -$22.5K ﹤0.01% 991
2020
Q3 		$26K Hold
697
– – ﹤0.01% 972
2020
Q2 		$20K Hold
697
– – ﹤0.01% 1024
2020
Q1 		$20K Hold
697
– – ﹤0.01% 1008
2019
Q4 		$24K Buy
+697
New +$19.3K ﹤0.01% 1001

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Daiwa Securities Group's BBIO Position: Q2 2026 in Review

Daiwa Securities Group reduced its BridgeBio Pharma (BBIO) stake by 2.5% in Q2 2026, selling an estimated $10.6K and leaving 5,991 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #992.

Daiwa Securities Group first reported a position in BBIO in Q4 2019 and has held it in 27 quarters since. The position peaked at $904K in Q2 2024. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Daiwa Securities Group held 5,991 shares of BridgeBio Pharma worth $446K as of Q2 2026.
  • Daiwa Securities Group sold 151 BridgeBio Pharma shares in Q2 2026, an estimated $10.6K.
  • BridgeBio Pharma made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #992 holding.
  • Daiwa Securities Group first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 27 quarters since.
  • Daiwa Securities Group's BridgeBio Pharma position peaked at $904K in Q2 2024.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.